XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Note 16 - Distribution Agreements
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
License, Collaboration, and Distribution Agreements [Text Block]

NOTE 16. DISTRIBUTION AGREEMENTS

 

Transactions under the Company’s major distribution agreements are recognized upon transfer of control of products sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns.

 

Product Sales Discounts and Allowances

 

The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the year ended December 31, 2023 (in thousands):

 

  

Chargebacks,

Discounts for

Prompt Payment

  

Other

Customer

Fees

  

Rebates

  

Total

 

Balance at December 31, 2022

 $1,673  $53  $81  $1,807 

Provision related to sales made in:

                

Current period

  716   321   106   1,143 

Payments and customer credits issued

  (1,476)  (362)  (166)  (2,004)

Balance at December 31, 2023

 $913  $12  $21  $946 

 

The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the year ended December 31, 2022 (in thousands):

 

  

Chargebacks,

Discounts for

Prompt Payment

  

Other

Customer

Fees

  

Rebates

  

Total

 

Balance at December 31, 2021

 $1,150  $83  $56  $1,289 

Provision related to sales made in:

                

Current period

  1,865   65   448   2,378 

Payments and customer credits issued

  (1,342)  (95)  (423)  (1,860)

Balance at December 31, 2022

 $1,673  $53  $81  $1,807 

 

Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies

 

Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company has also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During each of the years ended December 31, 2023 and 2022, the Company earned $0.1 million in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements.

 

Under these product distribution arrangements, the Company had a contract liability balance of $0.7 million and $1.6 million as of December 31, 2023 and 2022, respectively. The contract liability is included in accrued liabilities in the consolidated balance sheets.

 

Over-the-Counter Sales of Avenova Spray

 

Avenova Spray is offered for sale direct to U.S. customers primarily on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. During the years ended December 31, 2023 and 2022, the revenue generated from Avenova Spray in these channels was $6.1 million and $6.5 million, respectively.

 

DERMAdoctor Branded Products Distribution Agreements

 

DERMAdoctor branded products were sold through distribution arrangements with third parties such as Costco and others. During the years ended December 31, 2023 and 2022, the Company earned $0.7 million and $0.9 million, respectively, in sales revenue for its DERMAdoctor branded products from these distribution agreements.

 

Under these distribution arrangements, the Company had a contract liability balance of $0.2 million as of each of December 31, 2023 and 2022. The contract liability is included in accrued liabilities in the consolidated balance sheets.

Subsequent to December 31, 2023, on March 25, 2024, we closed the DERMAdoctor Divestiture. See additional information in Note 21, “Subsequent Events”.